Beijing Sun-Novo Stock Hits Day High with 6.07% Surge

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. has experienced a notable increase of 6.07% on March 5, 2026, reaching an intraday high of CNY 62.80. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 1.26% on the same day. Despite the positive movement today, the stock has faced challenges over the past week and month, with declines of 4.02% and 4.88%, respectively. However, over the past year, Beijing Sun-Novo has shown resilience, boasting a significant return of 41.9%, outperforming the China Shanghai Composite, which recorded a 22.49% increase. The company's market capitalization is approximately CNY 5,405 million, placing it in the mid-cap category within the pharmaceuticals and biotechnology sector. Key financial metrics indicate a price-to-earnings ratio of 48.00 and a return on equity of 11.14%. While the stock has generated a return of 33.69% over the past year, it has also faced a decline in profits by 23.5%. Overall, today's performance highlights the stock's volatility amid a mixed financial backdrop.